What is HC Wainwright's Forecast for Innoviva Q2 Earnings?

Innoviva, Inc. (NASDAQ:INVA - Free Report) - Equities research analysts at HC Wainwright issued their Q2 2025 earnings estimates for Innoviva in a research report issued to clients and investors on Monday, July 14th. HC Wainwright analyst R. Selvaraju expects that the biotechnology company will earn $0.57 per share for the quarter. HC Wainwright has a "Buy" rating and a $40.00 price objective on the stock. The consensus estimate for Innoviva's current full-year earnings is $0.33 per share. HC Wainwright also issued estimates for Innoviva's Q3 2025 earnings at $0.47 EPS, Q4 2025 earnings at $0.52 EPS, FY2025 earnings at $1.82 EPS, Q1 2026 earnings at $0.55 EPS, Q2 2026 earnings at $0.68 EPS, Q3 2026 earnings at $0.71 EPS, Q4 2026 earnings at $0.80 EPS and FY2026 earnings at $2.74 EPS.

Several other research firms have also recently weighed in on INVA. Cantor Fitzgerald began coverage on shares of Innoviva in a research note on Friday, July 11th. They issued an "overweight" rating and a $26.00 target price for the company. Wall Street Zen upgraded shares of Innoviva from a "hold" rating to a "buy" rating in a research note on Wednesday, April 30th.

Innoviva Stock Performance

Shares of NASDAQ INVA traded down $0.31 during mid-day trading on Wednesday, hitting $19.57. The company had a trading volume of 898,044 shares, compared to its average volume of 712,291. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.48 and a quick ratio of 2.30. The business's 50-day simple moving average is $19.91 and its 200-day simple moving average is $18.65. Innoviva has a 12 month low of $16.67 and a 12 month high of $22.00. The firm has a market cap of $1.23 billion, a P/E ratio of -19.38 and a beta of 0.37.

Innoviva (NASDAQ:INVA - Get Free Report) last released its earnings results on Wednesday, May 7th. The biotechnology company reported $0.25 earnings per share for the quarter. Innoviva had a negative net margin of 16.15% and a positive return on equity of 15.77%. The business had revenue of $88.63 million during the quarter.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in INVA. Parallel Advisors LLC raised its stake in shares of Innoviva by 157.5% in the second quarter. Parallel Advisors LLC now owns 1,849 shares of the biotechnology company's stock valued at $37,000 after acquiring an additional 1,131 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new position in shares of Innoviva in the first quarter valued at approximately $56,000. Tower Research Capital LLC TRC raised its stake in shares of Innoviva by 75.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 4,962 shares of the biotechnology company's stock valued at $86,000 after acquiring an additional 2,128 shares during the last quarter. GAMMA Investing LLC raised its stake in shares of Innoviva by 58.9% in the second quarter. GAMMA Investing LLC now owns 7,146 shares of the biotechnology company's stock valued at $144,000 after acquiring an additional 2,648 shares during the last quarter. Finally, Farther Finance Advisors LLC raised its stake in shares of Innoviva by 10.3% in the first quarter. Farther Finance Advisors LLC now owns 8,516 shares of the biotechnology company's stock valued at $153,000 after acquiring an additional 795 shares during the last quarter. Institutional investors own 99.12% of the company's stock.

Innoviva Company Profile

Innoviva, Inc engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.